

Cite this: *Chem. Sci.*, 2025, 16, 9049

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 14th March 2025
Accepted 23rd April 2025

DOI: 10.1039/d5sc02016f

rsc.li/chemical-science

Towards site-specific manipulation in cysteine-mediated redox signaling

Jing Yang ^{abc}

Cysteine sulfenic acid (SOH) modifications are pivotal in redox signaling, yet establishing their causal biological roles remains challenging due to methodological limitations. Traditional approaches often lack precision or disrupt non-redox cysteine functions. This perspective highlights two innovative chemical biology strategies to address these challenges: (1) integrating bioorthogonal cleavage chemistry with genetic code expansion for site-specific SOH incorporation in proteins of interest, enabling controlled activation of redox events, and (2) developing redox-targeted covalent inhibitors (TCIs) to selectively block SOH modifications. By bridging technological innovation with mechanistic inquiry, these strategies not only help elucidate SOH-mediated signaling networks for a better understanding of redox biology, but also hold therapeutic promise for precise redox medicine.

Cells sense and adapt to interior environmental changes or external stresses through intricate signaling mechanisms.¹ These processes often begin when signaling molecules bind to receptors on or within the cell, triggering cascades of biological events that amplify and fine-tune cellular responses. A cornerstone of signaling regulation is post-translational modification


(PTM), a mechanism first elucidated in the 1950s by Edmond Fischer and Edwin Krebs.² Their work revealed how adrenaline binding to its receptor initiates a phosphorylation cascade—a reversible enzymatic process mediated by kinases and phosphatases that ensures specificity in this canonical signaling pathway (Fig. 1A).

Over time, our understanding of signaling has expanded to include diverse signal molecules, such as reactive oxygen species (ROS).³ Hydrogen peroxide (H₂O₂), a non-radical ROS, exemplifies this complexity.⁴ While H₂O₂ is recognized as a signaling molecule, its reactive nature sparks debate. Specifically, H₂O₂ generally leads to non-enzymatic chemical reactions with specific atoms of target proteins, particularly cysteinyl thiols (SH). Among various products of H₂O₂-mediated oxidation, cysteine sulfenic acid (SOH, also known as sulfonylation) may serve as both a sensor and amplifier of H₂O₂ signals, playing a pivotal role in redox signaling pathways. Due to its labile nature, SOH is often considered an intermediate *en route* to additional cysteine redox modifications such as sulfinic acid (SO₂H), sulfonic acid (SO₃H), and persulfides (SSH). Thus, various chemical approaches have been developed for stabilizing this oxidative intermediate, serving as the method-of-choice for reliable detection of endogenous SOHs. Notably, the last decade has witnessed tremendous progress in the development of chemoselective SOH probes and chemo-proteomic technologies to enable global mapping of SOH modifications in intact cells, revealing relative specificity in their formation.^{5–9} This specificity arises from factors such as cysteine intrinsic reactivity, protein structural motifs, and local microenvironments.¹⁰ Seminal studies underscore the biological relevance of SOH. For example, the Toledano group demonstrated in 2002 that yeast cells employ a “redox relay” mechanism (Fig. 1B): the peroxidase Gpx3 senses H₂O₂, forms

^aGuangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou, China. E-mail: yangjing@ncpsb.org.cn

^bSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China

^cState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences – Beijing, Beijing Institute of Lifeomics, Beijing, China



Jing Yang

Dr Jing Yang earned his PhD from China Pharmaceutical University in 2012. Following that, he served as a postdoctoral fellow at Vanderbilt University from 2012 to 2015. In 2015, he was recruited as a Principal Investigator at the National Center for Protein Sciences – Beijing, with a joint appointment at the State Key Laboratory of Proteomics and Beijing Proteome Research Center. In the spring of 2023, he joined the Guangzhou National

Laboratory. The Yang lab is dedicated to advancing chemical proteomic technologies, addressing fundamental questions in redox biology, and exploring the druggable space of the cysteine redox proteome.




Fig. 1 Schematic of canonical signaling (A) and cysteine-mediated redox signaling (B).

SOH, and transfers oxidative signals *via* disulfide bonds to the transcription factor Yap1, regulating redox homeostasis.¹¹ Similar mechanisms, mediated by peroxidases, operate in plants and mammals.^{12–16} Beyond these canonical pathways, site-specific SOH modifications are proposed to influence diverse physiological processes. Mitochondrial H_2O_2 , for instance, induces SOH on thermogenic protein UCP1 C253 in brown fat, enhancing energy expenditure.¹⁷ In plants, SOH on C51 of the transcription factor CHE boosts salicylic acid production, enabling systemic disease resistance.¹⁸ Given that ROS production is thought to be a hallmark of pathogenesis and disease progression in many human diseases, additionally, emerging evidence demonstrates that site-specific SOH modifications play important roles in pathophysiological processes.^{19–21} For instance, the elevated SOH levels of pyruvate kinase M2 (PKM2) at C358 were observed in disease models of hyperglycemia and diabetes, and this specific cysteine oxidation event was potentially associated with the progression of diabetic glomerular pathology by decreasing PKM2 activity.¹⁹

Despite these advances, skepticism persists regarding the causal link between SOH modifications and biological outcomes. Current experimental approaches face limitations (Fig. 2A): gain-of-function methods (*e.g.*, adding exogenous oxidants or expressing H_2O_2 -generating enzymes) lack precision, while loss-of-function strategies (*e.g.*, chemical alkylation or genetic mutagenesis) disrupt non-redox cysteine roles, such as structural disulfide or metal binding. To address these challenges, new methodologies are warranted to selectively induce or block SOH modifications in specific proteins without perturbing other redox processes in living systems. This perspective highlights emerging chemical biology strategies for site-specific manipulation of SOH and discusses their potential to resolve longstanding debates in cysteine-mediated redox signaling. We further explore the translational promise of redox-based, targeted covalent inhibitors (TCIs), which could target dysregulated pathways in diseases linked to oxidative stress. By bridging mechanistic insights with innovative tools,

this field is poised to redefine our understanding of redox biology in health and disease.

Gain-of-function manipulation of specific SOH events on target proteins

Bioorthogonal cleavage chemistry, combined with genetic code expansion, has emerged as a transformative tool for precise protein manipulation in living systems.²² This approach enables spatially and temporally controlled activation of proteins by releasing functional groups on demand.^{23,24} Building on these advances, we propose leveraging bioorthogonal cleavage chemistry and genetic code expansion to achieve site-specific incorporation of SOH within a protein of interest (POI). By replacing a target cysteine residue with chemically “caged” unnatural amino acids (UAAs), the redox-sensitive SOH modification could be masked during protein synthesis and later activated *via* bioorthogonal cleavage chemistry under controlled conditions (Fig. 2B). Current bioorthogonal cleavage chemistry strategies predominantly focus on releasing amine or hydroxyl groups through transition-metal catalysis or small-molecule triggers, limiting their application to residues like lysine, serine, or tyrosine.²⁵ However, traditional photocaged cysteine derivatives offer a versatile solution.²⁶ For instance, light-controlled activation of catalytic cysteines has been demonstrated in enzymes such as DNA methyltransferase (DNMT), where a photocaged UAA temporarily blocks enzymatic activity until UV irradiation restores function.²⁷ This principle could be adapted to redox biology by developing analogous systems for SOH formation.

Despite this potential, photoactivation of Cys-SOH remains underexplored. Pioneering work by the Carroll group introduced photocaged cysteine sulfoxide analogs, where ultraviolet (UV) light cleaves photolabile groups (*e.g.*, *ortho*-nitrobenzyl, ONB or 4,5-dimethoxy-2-nitrobenzyl, DMNB, Fig. 2B) to generate SOH quantitatively in aqueous environments at neutral pH values.²⁸ Notably, these precursors resist reduction






Fig. 2 Traditional and emerging strategies for functional interrogating of cysteine-mediated redox signaling. (A) Traditional thiol-oriented strategies for manipulating cysteine-mediated redox signaling and their limitations. (B and C) Emerging sulfenic acid (SOH)-oriented manipulation strategies for site-specific interrogating of the causal link between cysteine-mediated redox signaling and biological outcomes in living systems. (B) Integrating bioorthogonal cleavage chemistry with genetic code expansion for site-specific SOH incorporation. For example, DMNB-caged cysteine sulfoxide could be used as an unnatural amino acid for site-specific incorporation of SOH in a protein of interest (POI) via genetic code expansion, and the photocaged SOH modification could be activated by ultraviolet irradiation. (C) Developing a redox-based target covalent inhibitor (TCI) to selectively block SOH modifications. For example, the nitroacetamide group could be used as a moderately reactive warhead for nucleophilic TCI design.

by using methionine sulfoxide reductase, ensuring intracellular stability. While incorporated into peroxidase Gpx3, such photocaged sulfoxides enabled controlled SOH formation, highlighting their potential utility for studying redox signaling. To extend this strategy to genetic encoding, orthogonal synthetase/tRNA pairs must be developed. While *EcLeu* synthetase—previously used to incorporate DMNB-caged serine²⁹—could theoretically adapt to DMNB-caged cysteine sulfoxide, experimental validation is needed. Alternatively, directed evolution of synthetases may yield systems with enhanced specificity. On the other hand, a key limitation of UV-dependent decaging is its unintended generation of ROS. Future efforts should prioritize bioorthogonal decaging methods that avoid ROS induction, ensuring precise SOH activation without perturbing redox homeostasis.

Loss-of-function manipulation of specific SOH events on target proteins

The success of covalent kinase inhibitors, such as the FDA (US Food and Drug Administration)-approved drugs afatinib and ibuprofen, demonstrates the feasibility of designing covalent

small molecules with high target specificity.³⁰ These inhibitors selectively bind to cysteine residues (Cys797 in the epidermal growth factor receptor and EGFR and Cys215 in Bruton's tyrosine kinase, BTK) through a two-step mechanism. First, the inhibitor reversibly associates with its target, positioning a weakly electrophilic group ("warhead") near a nucleophilic residue (typically cysteine in a reduced form). This proximity enables covalent bond formation, irreversibly blocking protein function. With this in mind, we reasoned that it is also possible for developing TCIs to afford loss-of-function manipulation of SOH events in a site/target-specific manner (Fig. 2C).

Progress in bioconjugation methods for chemoselective labeling and detecting SOH modifications has laid a foundation for such efforts.³¹ However, existing tools are primarily designed for broad profiling of SOH across the proteome, rather than selective targeting. A key challenge lies in balancing reactivity: while state-of-the-art chemoselective SOH warheads or probes prioritize strong labeling efficiency, TCIs require warheads with precisely tuned, moderate reactivity to avoid off-target effects. Early examples of redox-dependent TCIs include dimedone-based compounds, which pair this nucleophilic warhead with binding modules targeting protein tyrosine phosphatases

(PTPs).^{32,33} However, these initial designs lack proteome-wide specificity, and their biological impact on SOH-mediated PTP regulation remains unexplored. Peroxidases—critical sensors of H₂O₂ as aforementioned—represent another promising yet challenging target class for redox-based TCIs. These enzymes rely on reactive cysteine residues for catalysis, but their structural complexity has hindered small-molecule inhibitor development. Most known peroxidase inhibitors are discovered by serendipity or high-throughput screening rather than *de novo* structure-based design.^{34–37} Notably, they typically contain electrophilic groups that covalently modify catalytic/peroxidatic or resolving cysteines. Replacing these groups with nucleophilic warheads reactive toward SOH could offer a novel route to probe peroxidase-mediated redox signaling.

Beyond target-centric approaches, recent advances in combining covalent ligand screening and activity-based protein profiling (ABPP, a chemoproteomic strategy that employs covalent probes to directly interrogate protein function within complex proteomes³⁸) have provided versatile opportunities to discover reactive ligandable hotspots across complex proteomes and to generate small molecules that selectively bind challenging protein targets.^{39,40} This strategy was pioneered by Cravatt using ABPP to identify proteome-wide targets of a library of electrophilic covalent ligands by using competing individual ligands against a broad-spectrum thiol-reactive probe (*i.e.*, iodoacetamide-alkyne).⁴¹ Since its first report in 2016, the strategy has been widely used for ‘high-throughput’ serendipitous discovery of ligandable cysteines, leading to the identification of cysteine-oriented TCIs of proteins previously viewed as ‘undruggable’.^{42–48} Moreover, this strategy has also been adapted by targeting other amino acid residues including lysine,^{46,49–51} tyrosine,^{52–54} serine,⁵⁵ aspartate and glutamate,⁵⁶ and extends beyond cysteine as a source for TCI development. Inspired by these efforts, we reasoned that this compound-centric strategy could also be adapted to expand the ligandability map of the oxidized cysteine proteome and enable discovery of SOH-reactive ligands. Thus, we recently developed a library of 65 SOH-reactive compounds based on cyanoacetamide and nitroacetamide scaffolds (Fig. 2C), which exhibit mild reactivity toward SOHs.⁵⁷ Screening this library against

thousands of cellular SOHs identified 524 liganded sites on 441 proteins. Functional studies revealed that select compounds disrupt protein interactions: one ligand blocked oxidized PRXL2A from suppressing MAPK signaling, while others inhibited nuclear transport of HDGF or DNA repair by BCCIP. Though further optimization (*e.g.*, designing more advanced chemical probes through traditional structure–activity relationship-based methods) is needed to enhance specificity, this global map of ligand–SOH interactions provides a roadmap for developing TCIs that selectively inhibit SOH-driven signaling pathways.

Future outlook

Causal validation of SOH-mediated redox signaling remains a critical frontier in biology. While advances in SOH-specific probes and chemoproteomics have greatly expanded catalogs of SOH sites, their functional consequences in living systems are often obscured by technical limitations inherent to traditional methods. To address this, we propose two complementary chemical biology strategies: (1) integrating bioorthogonal cleavage chemistry with genetic code expansion to enable site-specific SOH incorporation in POIs, and (2) designing redox-dependent TCIs to selectively block site-specific SOH modifications in POIs. These approaches not only establish causal links between SOH events and their biological outcomes but also empower global mapping of SOH-driven protein interaction networks. For instance, POIs engineered with inducible SOHs could serve as baits for affinity purification-mass spectrometry (AP-MS)⁵⁸ or proximity labeling-mass spectrometry (PL-MS)⁵⁹ to identify downstream redox-relaying effectors or redox-dependent interacting partners that may empower the identification of ‘erasers’ (*e.g.*, reductases) of specific SOH events and redox-independent ‘readers’ of this type of modification (Fig. 3). In a complementary way, using a redox-dependent TCI allows us to chemically perturb one specific SOH event on a POI, followed by the measurements of resulting changes in the interacting partners of this target.

Beyond basic research, redox-based TCIs hold therapeutic promise. For example, oxidized cysteines in oncogenic targets




Fig. 3 Expanding SOH-driven protein interaction networks. (A) Combining the site-specific SOH release strategy and affinity purification (AP)-mass spectrometry to directly capture and identify redox-relaying partners of a specific SOH event on a protein-of-interest (POI); (B) combining the site-specific SOH release strategy and proximity labeling (PL)-mass spectrometry to identify redox-dependent interacting partners (*e.g.*, ‘readers’ or ‘erasers’) of a specific SOH event on a POI. IDs: identifications.



like EGFR or KRAS G12C may drive resistance to conventional electrophilic inhibitors, which fail to engage oxidized residues.^{60–62} Nucleophilic TCIs targeting these oxidized states could circumvent such resistance. However, challenges remain: the transient nature of SOH demands careful consideration of stoichiometry and irreversible oxidation, while distinguishing functional roles of reduced *versus* oxidized protein states adds complexity. Conversely, the context-dependent increase in SOH in disease states (e.g., cancers with elevated oxidative stress) offers opportunities for disease-state-specific targeting. Expanding libraries of nucleophilic warheads paired with optimized binding modules will accelerate discovery of druggable SOH sites and refine lead compounds.

Collectively, these strategies bridge technological innovation with biological inquiry, poised to transform our understanding of redox signaling. By engaging chemists and chemical biologists in refining precision tools, this nascent field promises not only mechanistic insights into redox biology but also novel therapeutic avenues for precise redox medicine.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Author contributions

J. Y. conceived the perspective and wrote the manuscript.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

The work was supported by grants from the National Key R&D Program of China (2022YFA1304700) to J. Y. and the National Natural Science Foundation of China (81973279 and 21922702) to J. Y.

References

- M. J. Lee and M. B. Yaffe, Protein Regulation in Signal Transduction, *Cold Spring Harbor Perspect. Biol.*, 2016, **8**, a005918.
- N. Kresge, R. D. Simoni and R. L. Hill, The process of reversible phosphorylation: the work of Edmond H. Fischer, *J. Biol. Chem.*, 2011, **286**, e1–e2.
- B. D'Autreaux and M. B. Toledano, ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis, *Nat. Rev. Mol. Cell Biol.*, 2007, **8**, 813–824.
- T. F. Brewer, F. J. Garcia, C. S. Onak, K. S. Carroll and C. J. Chang, Chemical approaches to discovery and study of sources and targets of hydrogen peroxide redox signaling through NADPH oxidase proteins, *Annu. Rev. Biochem.*, 2015, **84**, 765–790.
- L. Fu, K. Liu, R. B. Ferreira, K. S. Carroll and J. Yang, Proteome-Wide Analysis of Cysteine S-Sulphenylation Using a Benzothiazine-Based Probe, *Curr. Protoc. Protein Sci.*, 2019, **95**, e76.
- Y. Shi, L. Fu, J. Yang and K. S. Carroll, Wittig reagents for chemoselective sulfenic acid ligation enables global site stoichiometry analysis and redox-controlled mitochondrial targeting, *Nat. Chem.*, 2021, **13**, 1140–1150.
- J. Meng, L. Fu, K. Liu, C. Tian, Z. Wu, Y. Jung, R. B. Ferreira, K. S. Carroll, T. K. Blackwell and J. Yang, Global profiling of distinct cysteine redox forms reveals wide-ranging redox regulation in *C. elegans*, *Nat. Commun.*, 2021, **12**, 1415.
- J. Yang, V. Gupta, K. S. Carroll and D. C. Liebler, Site-specific mapping and quantification of protein S-sulphenylation in cells, *Nat. Commun.*, 2014, **5**, 4776.
- J. Yang, V. Gupta, K. A. Tallman, N. A. Porter, K. S. Carroll and D. C. Liebler, Global, in situ, site-specific analysis of protein S-sulphenylation, *Nat. Protoc.*, 2015, **10**, 1022–1037.
- H. Xiao, M. P. Jedrychowski, D. K. Schweppe, E. L. Huttlin, Q. Yu, D. E. Heppner, J. Li, J. Long, E. L. Mills, J. Szpyt, Z. He, G. Du, R. Garrity, A. Reddy, L. P. Vaites, J. A. Paulo, T. Zhang, N. S. Gray, S. P. Gygi and E. T. Chouchani, A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during Aging, *Cell*, 2020, **180**, 968–983.
- A. Delaunay, D. Pflieger, M. B. Barrault, J. Vinh and M. B. Toledano, A thiol peroxidase is an H₂O₂ receptor and redox-transducer in gene activation, *Cell*, 2002, **111**, 471–481.
- S. Stocker, M. Maurer, T. Ruppert and T. P. Dick, A role for 2-Cys peroxiredoxins in facilitating cytosolic protein thiol oxidation, *Nat. Chem. Biol.*, 2018, **14**, 148–155.
- M. C. Sobotta, W. Liou, S. Stocker, D. Talwar, M. Oehler, T. Ruppert, A. N. Scharf and T. P. Dick, Peroxiredoxin-2 and STAT3 form a redox relay for H₂O₂ signaling, *Nat. Chem. Biol.*, 2015, **11**, 64–70.
- G. Bi, M. Hu, L. Fu, X. Zhang, J. Zuo, J. Li, J. Yang and J. M. Zhou, The cytosolic thiol peroxidase PRXIIIB is an intracellular sensor for H₂O₂ that regulates plant immunity through a redox relay, *Nat. Plants*, 2022, **8**, 1160–1175.
- T. N. Vo, J. Malo Pueyo, K. Wahni, D. Ezerina, J. Bolduc and J. Messens, Prdx1 Interacts with ASK1 upon Exposure to H₂O₂ and Independently of a Scaffolding Protein, *Antioxidants*, 2021, **10**, 1060.
- P. E. Pace, A. V. Peskin, A. Konigstorfer, C. J. Jasoni, C. C. Winterbourn and M. B. Hampton, Peroxiredoxin interaction with the cytoskeletal-regulatory protein CRMP2: investigation of a putative redox relay, *Free Radical Biol. Med.*, 2018, **129**, 383–393.
- E. T. Chouchani, L. Kazak, M. P. Jedrychowski, G. Z. Lu, B. K. Erickson, J. Szpyt, K. A. Pierce, D. Laznik-Bogoslavski, R. Vetrivelan, C. B. Clish, A. J. Robinson, S. P. Gygi and B. M. Spiegelman, Mitochondrial ROS regulate thermogenic energy expenditure and sulphenylation of UCP1, *Nature*, 2016, **532**, 112–116.
- L. Cao, S. Karapetyan, H. Yoo, T. Chen, M. Mwimba, X. Zhang and X. Dong, H₂O₂ sulphenylates CHE, linking



- local infection to the establishment of systemic acquired resistance, *Science*, 2024, **385**, 1211–1217.
- 19 W. Qi, H. A. Keenan, Q. Li, A. Ishikado, A. Kannt, T. Sadowski, M. A. Yorek, I. H. Wu, S. Lockhart, L. J. Coppey, A. Pfenninger, C. W. Liew, G. Qiang, A. M. Burkart, S. Hastings, D. Pober, C. Cahill, M. A. Niewczasz, W. J. Israelsen, L. Tinsley, I. E. Stillman, P. S. Amenta, E. P. Feener, M. G. Vander Heiden, R. C. Stanton and G. L. King, Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction, *Nat. Med.*, 2017, **23**, 753–762.
 - 20 N. Zhou, J. Chen, Z. Ling, C. Zhang, Y. Zhou, D. Wang, L. Zhou, Z. Wang, N. Sun, X. Wang, H. Zhang, K. Tang, J. Ma, J. Lv and B. Huang, Aryl hydrocarbon receptor sulfenylation promotes glycogenolysis and rescues cancer chemoresistance, *J. Clin. Invest.*, 2023, **133**, e170753.
 - 21 B. Mu, Y. Zeng, L. Luo and K. Wang, Oxidative stress-mediated protein sulfenylation in human diseases: past, present, and future, *Redox Biol.*, 2024, **76**, 103332.
 - 22 J. Wang, X. Wang, X. Fan and P. R. Chen, Unleashing the Power of Bond Cleavage Chemistry in Living Systems, *ACS Cent. Sci.*, 2021, **7**, 929–943.
 - 23 J. Wang, Y. Liu, Y. Liu, S. Zheng, X. Wang, J. Zhao, F. Yang, G. Zhang, C. Wang and P. R. Chen, Time-resolved protein activation by proximal decaging in living systems, *Nature*, 2019, **569**, 509–513.
 - 24 S. Tang, A. T. Beattie, L. Kafkova, G. Petris, N. Huguenin-Dezot, M. Fiedler, M. Freeman and J. W. Chin, Mechanism-based traps enable protease and hydrolase substrate discovery, *Nature*, 2022, **602**, 701–707.
 - 25 M. Charette, C. Rosenblum, O. Shade and A. Deiters, Optogenetics with Atomic Precision horizontal line A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion, *Chem. Rev.*, 2025, **125**, 1663–1717.
 - 26 C. Y. Chang, B. Niblack, B. Walker and H. Bayley, A photogenerated pore-forming protein, *Chem. Biol.*, 1995, **2**, 391–400.
 - 27 J. Wolffgramm, B. Buchmuller, S. Palei, A. Munoz-Lopez, J. Kanne, P. Janning, M. R. Schweiger and D. Summerer, Light-Activation of DNA-Methyltransferases, *Angew Chem. Int. Ed. Engl.*, 2021, **60**, 13507–13512.
 - 28 J. Pan and K. S. Carroll, Light-Mediated Sulfenic Acid Generation from Photocaged Cysteine Sulfoxide, *Org. Lett.*, 2015, **17**, 6014–6017.
 - 29 E. A. Lemke, D. Summerer, B. H. Geierstanger, S. M. Brittain and P. G. Schultz, Control of protein phosphorylation with a genetically encoded photocaged amino acid, *Nat. Chem. Biol.*, 2007, **3**, 769–772.
 - 30 L. Boike, N. J. Henning and D. K. Nomura, Advances in covalent drug discovery, *Nat. Rev. Drug Discovery*, 2022, **21**, 881–898.
 - 31 L. J. Alcock, M. V. Perkins and J. M. Chalker, Chemical methods for mapping cysteine oxidation, *Chem. Soc. Rev.*, 2018, **47**, 231–268.
 - 32 S. E. Leonard, F. J. Garcia, D. S. Goodsell and K. S. Carroll, Redox-based probes for protein tyrosine phosphatases, *Angew Chem. Int. Ed. Engl.*, 2011, **50**, 4423–4427.
 - 33 F. J. Garcia and K. S. Carroll, Redox-based probes as tools to monitor oxidized protein tyrosine phosphatases in living cells, *Eur. J. Med. Chem.*, 2014, **88**, 28–33.
 - 34 C. X. Liu, Q. Q. Yin, H. C. Zhou, Y. L. Wu, J. X. Pu, L. Xia, W. Liu, X. Huang, T. Jiang, M. X. Wu, L. C. He, Y. X. Zhao, X. L. Wang, W. L. Xiao, H. Z. Chen, Q. Zhao, A. W. Zhou, L. S. Wang, H. D. Sun and G. Q. Chen, Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells, *Nat. Chem. Biol.*, 2012, **8**, 486–493.
 - 35 J. D. Haraldsen, G. Liu, C. H. Botting, J. G. Walton, J. Storm, T. J. Phalen, L. Y. Kwok, D. Soldati-Favre, N. H. Heintz, S. Muller, N. J. Westwood and G. E. Ward, Identification of Conoidin A as a Covalent Inhibitor of Peroxiredoxin II, *Org. Biomol. Chem.*, 2009, **7**, 3040–3048.
 - 36 W. Wei, C. Ma, Y. Cao, L. Yang, Z. Huang, D. Qin, Y. Chen, C. Liu, L. Xia, T. Wang, H. Lei, Y. Yu, M. Huang, Y. Tong, H. Xu, F. Gao, J. Zhang and Y. L. Wu, Identification of H7 as a novel peroxiredoxin I inhibitor to induce differentiation of leukemia cells, *Oncotarget*, 2016, **7**, 3873–3883.
 - 37 H. Xu, H. Zhao, C. Ding, D. Jiang, Z. Zhao, Y. Li, X. Ding, J. Gao, H. Zhou, C. Luo, G. Chen, A. Zhang, Y. Xu and H. Zhang, Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1, *Signal Transduction Targeted Ther.*, 2023, **8**, 51.
 - 38 E. O. J. Porta and P. G. Steel, Activity-based protein profiling: A graphical review, *Curr. Res. Pharmacol. Drug Discov.*, 2023, **5**, 100164.
 - 39 M. J. Niphakis and B. F. Cravatt, Ligand discovery by activity-based protein profiling, *Cell Chem. Biol.*, 2024, **31**, 1636–1651.
 - 40 I. Forrest and C. G. Parker, Proteome-Wide Fragment-Based Ligand and Target Discovery, *Isr. J. Chem.*, 2023, **63**, e202200098.
 - 41 K. M. Backus, B. E. Correia, K. M. Lum, S. Forli, B. D. Horning, G. E. Gonzalez-Paez, S. Chatterjee, B. R. Lanning, J. R. Teijaro, A. J. Olson, D. W. Wolan and B. F. Cravatt, Proteome-wide covalent ligand discovery in native biological systems, *Nature*, 2016, **534**, 570–574.
 - 42 S. G. Kathman, S. J. Koo, G. L. Lindsey, H. L. Her, S. M. Blue, H. Li, S. Jaensch, J. R. Remsberg, K. Ahn, G. W. Yeo, B. Ghosh and B. F. Cravatt, Remodeling oncogenic transcriptomes by small molecules targeting NNO, *Nat. Chem. Biol.*, 2023, **19**, 825–836.
 - 43 M. E. Kavanagh, B. D. Horning, R. Khattri, N. Roy, J. P. Lu, L. R. Whitby, E. Ye, J. C. Brannon, A. Parker, J. M. Chick, C. L. Eissler, A. J. Wong, J. L. Rodriguez, S. Rodiles, K. Masuda, J. R. Teijaro, G. M. Simon, M. P. Patricelli and B. F. Cravatt, Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine, *Nat. Chem. Biol.*, 2022, **18**, 1388–1398.
 - 44 E. Njomen, R. E. Hayward, K. E. DeMeester, D. Ogasawara, M. M. Dix, T. Nguyen, P. Ashby, G. M. Simon, S. L. Schreiber, B. Melillo and B. F. Cravatt, Multi-tiered



- chemical proteomic maps of tryptoline acrylamide-protein interactions in cancer cells, *Nat. Chem.*, 2024, **16**, 1592–1604.
- 45 E. V. Vinogradova, X. Zhang, D. Remillard, D. C. Lazar, R. M. Suci, Y. Wang, G. Bianco, Y. Yamashita, V. M. Crowley, M. A. Schafroth, M. Yokoyama, D. B. Konrad, K. M. Lum, G. M. Simon, E. K. Kemper, M. R. Lazear, S. Yin, M. M. Blewett, M. M. Dix, N. Nguyen, M. N. Shokhirev, E. N. Chin, L. L. Lairson, B. Melillo, S. L. Schreiber, S. Forli, J. R. Teijaro and B. F. Cravatt, An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells, *Cell*, 2020, **182**, 1009–1026.
 - 46 Y. Wang, M. M. Dix, G. Bianco, J. R. Remsberg, H. Y. Lee, M. Kalocsay, S. P. Gygi, S. Forli, G. Vite, R. M. Lawrence, C. G. Parker and B. F. Cravatt, Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs, *Nat. Chem.*, 2019, **11**, 1113–1123.
 - 47 X. Zhang, V. M. Crowley, T. G. Wucherpennig, M. M. Dix and B. F. Cravatt, Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16, *Nat. Chem. Biol.*, 2019, **15**, 737–746.
 - 48 Y. Zhang, Z. Liu, M. Hirschi, O. Brodsky, E. Johnson, S. J. Won, A. Nagata, D. Bezwada, M. D. Petroski, J. D. Majumdar, S. Niessen, T. VanArsdale, A. M. Gilbert, M. M. Hayward, A. E. Stewart, A. R. Nager, B. Melillo and B. F. Cravatt, An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes, *Nat. Chem. Biol.*, 2025, **21**, 420–431.
 - 49 M. E. Abbasov, M. E. Kavanagh, T. A. Ichu, M. R. Lazear, Y. Tao, V. M. Crowley, C. W. Am Ende, S. M. Hacker, J. Ho, M. M. Dix, R. Suci, M. M. Hayward, L. L. Kiessling and B. F. Cravatt, A proteome-wide atlas of lysine-reactive chemistry, *Nat. Chem.*, 2021, **13**, 1081–1092.
 - 50 S. M. Hacker, K. M. Backus, M. R. Lazear, S. Forli, B. E. Correia and B. F. Cravatt, Global profiling of lysine reactivity and ligandability in the human proteome, *Nat. Chem.*, 2017, **9**, 1181–1190.
 - 51 A. Cuesta and J. Taunton, Lysine-Targeted Inhibitors and Chemoproteomic Probes, *Annu. Rev. Biochem.*, 2019, **88**, 365–381.
 - 52 H. S. Hahm, E. K. Toroitich, A. L. Borne, J. W. Brulet, A. H. Libby, K. Yuan, T. B. Ware, R. L. McCloud, A. M. Ciancone and K. L. Hsu, Global targeting of functional tyrosines using sulfur-triazole exchange chemistry, *Nat. Chem. Biol.*, 2020, **16**, 150–159.
 - 53 J. W. Brulet, A. L. Borne, K. Yuan, A. H. Libby and K. L. Hsu, Liganding Functional Tyrosine Sites on Proteins Using Sulfur-Triazole Exchange Chemistry, *J. Am. Chem. Soc.*, 2020, **142**, 8270–8280.
 - 54 A. M. Ciancone, S. Hosseinibarkooie, D. L. Bai, A. L. Borne, H. A. Ferris and K. L. Hsu, Global profiling identifies a stress-responsive tyrosine site on EDC3 regulating biomolecular condensate formation, *Cell Chem. Biol.*, 2022, **29**, 1709–1720.
 - 55 H. A. Sharma, M. Bielecki, M. A. Holm, T. M. Thompson, Y. Yin, J. B. Cravatt, T. B. Ware, A. Reed, M. Nassir, T. E. Ewing, B. Melillo, J. F. Bazan, P. S. Baran and B. F. Cravatt, Proteomic Ligandability Maps of Phosphorus(V) Stereoprobes Identify Covalent TLCD1 Inhibitors, *bioRxiv*, 2025, preprint, DOI: [10.1101/2025.01.31.635883](https://doi.org/10.1101/2025.01.31.635883).
 - 56 K. Bach, B. L. H. Beerkens, P. R. A. Zanon and S. M. Hacker, Light-Activatable, 2,5-Disubstituted Tetrazoles for the Proteome-wide Profiling of Aspartates and Glutamates in Living Bacteria, *ACS Cent. Sci.*, 2020, **6**, 546–554.
 - 57 L. Fu, Y. Jung, C. Tian, R. B. Ferreira, R. Cheng, F. He, J. Yang and K. S. Carroll, Nucleophilic covalent ligand discovery for the cysteine redoxome, *Nat. Chem. Biol.*, 2023, **19**, 1309–1319.
 - 58 A. Bauer and B. Kuster, Affinity purification-mass spectrometry. Powerful tools for the characterization of protein complexes, *Eur. J. Biochem.*, 2003, **270**, 570–578.
 - 59 W. Qin, K. F. Cho, P. E. Cavanagh and A. Y. Ting, Deciphering molecular interactions by proximity labeling, *Nat. Methods*, 2021, **18**, 133–143.
 - 60 T. H. Truong, P. M. Ung, P. B. Palde, C. E. Paulsen, A. Schlessinger and K. S. Carroll, Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase, *Cell Chem. Biol.*, 2016, **23**, 837–848.
 - 61 M. V. Huynh, D. Parsonage, T. E. Forshaw, V. R. Chirasani, G. A. Hobbs, H. Wu, J. Lee, C. M. Furdui, L. B. Poole and S. L. Campbell, Oncogenic KRAS G12C: kinetic and redox characterization of covalent inhibition, *J. Biol. Chem.*, 2022, **298**, 102186.
 - 62 P. A. Schwartz, P. Kuzmic, J. Solowiej, S. Bergqvist, B. Bolanos, C. Almaden, A. Nagata, K. Ryan, J. Feng, D. Dalvie, J. C. Kath, M. Xu, R. Wani and B. W. Murray, Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 173–178.

